Get the Stockscreener App
5.15
1.63%
-0.08
Amylyx Pharmaceuticals Inc stock is traded at $5.15, with a volume of 279.73K.
It is down -1.63% in the last 24 hours and up +10.41% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
See More
Previous Close:
$5.23
Open:
$5.23
24h Volume:
279.73K
Relative Volume:
0.20
Market Cap:
$357.82M
Revenue:
$380.79M
Net Income/Loss:
$49.27M
P/E Ratio:
-4.1532
EPS:
-1.24
Net Cash Flow:
$10.68M
1W Performance:
+2.49%
1M Performance:
+10.41%
6M Performance:
+185.83%
1Y Performance:
-59.30%
1-Day Range:
$5.07
$5.30
1-Week Range:
$4.5701
$5.88
52-Week Range:
$1.575
$19.95
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| AMLX | 5.13 | 357.82M | 380.79M | 49.27M | 10.68M | -1.24 |
| VRTX | 446.52 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.50 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.90 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.19 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Upgraded by Baird R W - MarketBeat
Baird Upgrades Amylyx Pharmaceuticals (AMLX) - MSN
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise - MSN
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise (NASDAQ:AMLX) - Seeking Alpha
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded by Robert W. Baird to Outperform Rating - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Update - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2024 Earnings Call Transcript - Insider Monkey
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023) - Yahoo Finance
Amylyx Pharmaceuticals (NASDAQ:AMLX) Given New $12.00 Price Target at HC Wainwright - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Amylyx Pharmaceuticals Q3 2024 Financial Highlights - TipRanks
Amylyx Pharmaceuticals Inc. (AMLX) Quarterly 10-Q Report - Quartz
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Amylyx Reports Mixed Q3: Positive Trial Data Despite $72.7M Loss, Cash Runway Into 2026 | AMLX Stock News - StockTitan
Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday - MarketBeat
Vanguard Group Inc's Strategic Reduction in Amylyx Pharmaceutica - GuruFocus.com
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise - Simply Wall St
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - StockTitan
abrdn plc Buys 1,853,995 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Levi & Korsinsky Reminds Amylyx Investors of the Pending Class A - GuruFocus.com
Short Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Declines By 21.1% - MarketBeat
Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc - Yahoo Finance
Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharma - GuruFocus.com
Amylyx upgraded to buy by BofA on hypoglycemia drug potential - MSN
BofA upgrades Amylyx stock to Buy rating By Investing.com - Investing.com Australia
BofA upgrades Amylyx stock to Buy rating - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded to Buy by Bank of America - MarketBeat
Levi & Korsinsky Announces the Filing of a Securities Class Acti - GuruFocus.com
October 2024's US Penny Stocks Poised For Growth - Simply Wall St
Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial - MSN
Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments - Insider Monkey
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week - MSN
Amylyx shares reiterate Buy rating on trial data - Investing.com
Amylyx shares reiterate Buy rating on trial data By Investing.com - Investing.com UK
Amylyx Pharmaceuticals (NASDAQ:AMLX) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright maintains Buy rating on Amylyx shares on trial data - Investing.com
H.C. Wainwright maintains Buy rating on Amylyx shares on trial data By Investing.com - Investing.com UK
Amylyx’s AMX0035 shows promise in Phase II Wolfram syndrome trial - Clinical Trials Arena
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug - Yahoo Finance
Leerink maintains Market Perform rating on Amylyx stock on new data - Investing.com
Leerink maintains Market Perform rating on Amylyx stock on new data By Investing.com - Investing.com South Africa
Amylyx reports positive trial results for Wolfram syndrome treatment - Investing.com India
Amylyx reports positive trial results for Wolfram syndrome treatment By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome - StockTitan
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 - BioSpace
Amyotrophic Lateral Sclerosis Market 2034 | Mitsubishi Tanabe - openPR
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Millennium Management LLC - MarketBeat
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):